Ask Warren

InBody

041830 · KOSDAQ · ₩041830 · 인바디

₩45,700▼ ₩700 (1.51%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y +56.78%
Market cap
₩616B
Enterprise value
₩551B
P/E
13.2×
P/B
1.8×
Dividend yield
1.3%
ROE
13.5%
Net margin
17.6%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−37.8% from the high

₩26,200Today: ₩45,150 – ₩46,600₩73,500

Returns

  • 1W−5.3%
  • 1M−15.1%
  • 3M−2.0%
  • 6M+54.9%
  • YTD+39.5%
  • 1Y+56.8%
Volume today
44,846
0.8× the 20-day average
Traded today
₩2B
Listed shares
13,480,882
EPS (12 months)
₩3,453
Earnings yield 7.6%
SellBuy
AI research · InitiationInBody: Profit Recovery and a Sharp One-Year Rally Leave the Shares Near the Model EstimateThe filings show a financially sound company with no reported borrowings, a recovering margin and growing revenue.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

42Quiet
  • BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: A positive milestone story with no financial impact stated. Community: 0 bullish, 0 bearish posts this week.
  • MomentumWeak-15.8% over the last month; the price is below its 20-day average.
  • News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 29: sell ₩184M at the close (6.5% of 20-day average trading value)

Sep 30Last 20 trading days (% of average trading value)Oct 29

On its 14 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 12.8% of trading value and pointed the same way 10 of 14 times.

  • 2× KODEX KOSDAQ150 Leverage −₩128M
  • -1× KODEX KOSDAQ150 Futures Inverse −₩32M
  • 2× TIGER KOSDAQ150 Leverage −₩16M
  • 2× RISE KOSDAQ150 Futures Leverage −₩6M
  • -1× TIGER KOSDAQ150 Futures Inverse −₩1M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

InBody stock overview

InBody (인바디, KRX: 041830) is listed on KOSDAQ, in the Medical & precision devices sector. InBody is a Seoul-headquartered Korean maker of medical devices, operating through 18 subsidiaries, 4 in Korea and 14 overseas. Its shares closed at ₩45,700 on Oct 29, 2026, down 1.51% on the day, giving it a market value of ₩616B.

Key facts

Market cap
₩616B
Sector
Medical & precision devices
Latest price change
−1.51%
As of
Oct 29, 2026
Main business
InBody is a Seoul-headquartered Korean maker of medical devices, operating through 18 subsidiaries, 4 in Korea and 14 overseas.

Quick answers about InBody

What does InBody do?
InBody is a Seoul-headquartered Korean maker of medical devices, operating through 18 subsidiaries, 4 in Korea and 14 overseas. Its main products are body composition analyzers, automatic blood pressure monitors, home-use body composition analyzers, height and weight measurers, and management software. It sells through direct sales and domestic and overseas distributor networks to hospitals and clinics, fitness centers, military units, schools and government offices, companies, and individual consumers.
What is the market cap of InBody?
The market capitalisation of InBody was ₩616B at the close on Oct 29, 2026.
Who are the largest shareholders of InBody?
According to the latest official filings, the largest reported holders are Cha Gi-cheol (28.66%, as of Dec 2, 2024); Cha In-jun (28.20%, as of Sep 21, 2026); Fidelity Management & Research Company LLC (9.79%, as of Sep 10, 2026).
When is the next earnings report from InBody?
Korean companies rarely announce results dates in advance. Based on when InBody filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own InBody?
Yes. The National Pension Service held 5.30% of InBody shares as of Oct 2, 2026.

Company profile

InBody is a Seoul-headquartered Korean maker of medical devices, operating through 18 subsidiaries, 4 in Korea and 14 overseas. Its main products are body composition analyzers, automatic blood pressure monitors, home-use body composition analyzers, height and weight measurers, and management software. It sells through direct sales and domestic and overseas distributor networks to hospitals and clinics, fitness centers, military units, schools and government offices, companies, and individual consumers. Overseas sales account for most of its revenue, with the United States as its largest market.

Written by AI from the company's latest annual report.

Korean name
인바디
Sector
Medical & precision devices
Themes
Medical devicesAI healthcare
CEO
차기철 (단독대표)
Founded
May 1996
Listed
Dec 2000
Listed shares
13,480,882
Fiscal year ends
Month 12
Website
www.inbody.com

Similar companies

Recent news

News · Chosun Biz·

'42kg, InBody measurement impossible' Shin Ji looks unwell; she personally addresses health concerns: "suffering from a cold" [Oh!Ssen Issue]

InBody₩45,700▼1.51%
Read the original ↗

Predicted impact: Low

Celebrity health rumor with a minor investment in a related company; no material size.

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: InBody / 인바디 / 041830 / KRX:041830

Source: KRX statistical information